Auto-antibodies, HLA and PTPN22: Susceptibility markers for rheumatoid arthritis

Rheumatology

Volumn 47, Issue 2, 2008, Pages 138-141

  Orozco, G ^a   Pascual Salcedo, D ^b   Lopez Nevot M A ^c   Cobo, T ^b   Cabezon A ^b   Martin Mola E ^b   Balsa, A ^b   Martin J ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Auto antibodies; Cyclic citrullinated peptides; HLA DRB1; Polymorphism; PTPN22 gene; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 22; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTHROPATHY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ADULT; AGE OF ONSET; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; VARIATION (GENETICS);

EID: 38649123708     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem343     Document Type: Article

References (29)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Newton JL, Harney SM, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun 2004;5:151-7.
3. Begovich AB, Carlton VE, Honigberg LA et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (ptpn22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75:330-7.
4. Orozco G, Sanchez E, Gonzalez-Gay MA et al. Association of a functional single-nucleotide polymorphism of ptpn22, encoding lymphold protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005;52:219-24.
5. Huizings. TW, Amos CI, van der Helm-van Mil AH et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DR81 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
6. de Vries RR, Huizinga TW, Toes RE. HLA and RA revisited: Citrultinated food for the SE hypothesis, the DR6 effect, and nima. Hum Immunol 2006;67:454-9.
7. van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: The emerging role of anticilrulline autoimmunity in rheumatoid arthritis. J Immunol 2005;175:5575-80.
8. Lee AT, Li W, Uew A et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun 2005;6:129-33.
9. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Thar 2005:8:R19.
10. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern sweden. Arthritis Res Ther 2007;9:R56.
11. Feitsma AL, Toes RE, Begovich AB et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: The effect of the PTPN22 1858T-aflele in! anti-citrullinated peptide antibody positive patients. Rheumatology 2007;46:1092-5.
12. Amett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Salvador G, Gomez A, Vines O et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 2003;42:972-5.
14. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated paptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheurn 2006;54:1117-21.
15. van Gaalen FA, van Aken J, Huizinga TW et al. Association between HLA does II genes and autoantibodies to cyclic citrullinated peptides (CCPS) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
16. Berglin E, Padyukov L, Sundin U et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Thar 2004;6:R303-8.
17. de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: To be or not to be anti-CCP positive. J Autoimmun 2005;25(Suppl 1):21-5.
18. Kaltenhauser S, Pierer M, Arnold S et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rhoumatology 2007;46.100-4.
19. Cha S, Choi CB, Han TU, Kang CP, Kang C, Bae SC. Association of anti-cyclic citrullinated peptide antibody levels with PAD14 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum 2007;56:1454-63.
20. Furuya T, Hakoda M, Ichikawa N et al. Differential association of HLA-DRB1 alleles in japanese patients with early rheumatoid arthritis in relationship to autoantibodies to cyclic citrullinated peptide. Clin Exp Rheumatol 2007;25:219-24.
21. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005;52:3058-62.
22. Irigoyen P, Lee AT, Waner MH et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Contrasting effects of HLA-DR3 and the shared epitope allelles. Arthritis Rheum 2005;52:3813-8.
23. Zanelli E, Jones G, Pascual M et al. The tolomeric part of the HLA region predisposes to rheumatoid arthritis independently of the class II loci. Hum Immunol 2001;62:75-84.
24. Pascual M, Mataran L, Jones G et al. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes. Scand J Rheumatol 2002;31:275-8.
25. van der Helm-van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE. An independent role of protective HLA class II alleles In rheumatoid arthritis severity and susceptibility. Arthritis Rheum 2005;52:2637-44.
26. Hinks A, Barton A, John S et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005;52:1694-9.
27. van Oene M, Wintle RF, Liu X et al. Association of the lymphoid tyrosine phosphetase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum 2005;52:1993-8.
28. Rueda B, Nunez C, Orozoo G et al. C185ST functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition. Hum Immunol 2005;66:848-52.
29. Kyogoku C, Langefeld CD, Ortmann WA et al. Genetic association of the B620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004;75:504-7.